Striatal Vulnerability in Huntington's Disease: Neuroprotection Versus Neurotoxicity

• Published in: Brain sciences Vol. 7; no. 6; p. 63
• Main Authors: Morigaki, Ryoma, Goto, Satoshi
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 07.06.2017; MDPI
• Subjects: Huntingtin; Huntington's disease; Interneurons; matrix; medium spiny neuron; Neostriatum; Neurodegeneration; Neuroprotection; Neurotoxicity; Parvalbumin; pathophysiology; Polyglutamine; Review; Spiny neurons; striatum; striosome; Trinucleotide repeat diseases; Trinucleotide repeats; striosome; medium spiny neuron; striatum; huntingtin; pathophysiology; Huntington’s disease; matrix
• ISSN: 2076-3425; 2076-3425
• DOI: 10.3390/brainsci7060063

Huntington's disease (HD) is an autosomal dominant neurodegenerative disease caused by the expansion of a CAG trinucleotide repeat encoding an abnormally long polyglutamine tract (PolyQ) in the huntingtin (Htt) protein. In HD, striking neuropathological changes occur in the striatum, including loss of medium spiny neurons and parvalbumin-expressing interneurons accompanied by neurodegeneration of the striosome and matrix compartments, leading to progressive impairment of reasoning, walking and speaking abilities. The precise cause of striatal pathology in HD is still unknown; however, accumulating clinical and experimental evidence suggests multiple plausible pathophysiological mechanisms underlying striatal neurodegeneration in HD. Here, we review and discuss the characteristic neurodegenerative patterns observed in the striatum of HD patients and consider the role of various huntingtin-related and striatum-enriched proteins in neurotoxicity and neuroprotection.